Meeting
2018 ASCO Annual Meeting
Phase 1 study of pegargiminase combined with cisplatin and pemetrexed in patients with ASS1-deficient uveal melanoma.
Authors
Pui Ying Chan
Barts Health NHS Trust, London, United Kingdom
Pui Ying Chan , Melissa Mary Phillips , Ramsay Khadeir , Stephen Ellis , Jim Thomson , Amanda Johnston , Xiaoxing Feng , Bor-Wen Wu , John S. Bomalaski , Michael Sheaff , Peter Wojciech Szlosarek
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT02029690
Citation
J Clin Oncol 36, 2018 (suppl; abstr 2589)
DOI
10.1200/JCO.2018.36.15_suppl.2589
Abstract #
2589
Poster Bd #
415
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Expansion study of ADI-PEG 20, pemetrexed and cisplatin in patients with ASS1-deficient malignant pleural mesothelioma (TRAP).
First Author: Melissa Phillips
Poster
2019 ASCO Annual Meeting
Phase 1 dose-expansion study of pegylated arginine deiminase, cisplatin, and pemetrexed in patients with argininosuccinate synthetase 1 (ASS1)–deficient non-squamous non-small cell lung cancer.
First Author: Akhila Ganeshi Wimalasingham
Poster
2018 ASCO Annual Meeting
Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.
First Author: Nathaniel R. Evans
Poster
2015 ASCO Annual Meeting
Phase I study of ADI-PEG 20 in combination with pemetrexed and cisplatin (TRAP) in patients with ASS1-deficient mesothelioma and non-squamous lung cancer.
First Author: Peter Wojciech Szlosarek